An innovative research effort has found that administering stem cells to fetuses affected by spina bifida as part of a surgical repair could constitute a "important advancement" in treating birth defects.
Study Parameters and Security
The US-based trial examined six developing infants with the 'open' form of spina bifida. Medical teams placed mother's placental stem cells to the surface of the developing neural column while the defect was being closed.
Importantly, the cell therapy demonstrated a favorable safety profile. The study team reported that the treatment did not lead to cancerous growths, disrupt the healing process, or block the correction of associated brain abnormalities.
Promising Outcomes
Magnetic resonance imaging performed on the newborns confirmed a full resolution of brainstem displacement in each of the babies. This brain structure normalization is a key indicator for better mobility and function.
"In the event it allows additional babies capable of walking who previously could not, then it would become their standard of care," commented the principal investigator. "The results are extremely promising and open the door to a variety of prospective innovative interventions."
Future Implications and Hope
Experts not involved in the trial indicated that further confirmation of these observed advantages could announce a "new era" in prenatal intervention. The possibility of ameliorating neural deficits seen in utero is viewed as a revolutionary objective.
Particularly welcome would be advancements for continence and digestive health, which are frequent complications for people affected by this disorder.
Looking Ahead
Although this preliminary study focused on a handful of cases, its established security and encouraging indicators provide a strong foundation for broader investigative efforts. The combination of regenerative medicine with current in-utero repair procedures offers substantial hope for changing life trajectories for future generations with myelomeningocele.